201 related articles for article (PubMed ID: 8868947)
1. [Axillary lymph node dissection in clinically occult breast cancer].
Le Bouëdec G; Pomel C; Chamussy E; Feillel V; de Latour M; Dauplat J
Bull Cancer; 1996 Jul; 83(7):581-8. PubMed ID: 8868947
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma.
Topps A; Clay V; Absar M; Howe M; Lim Y; Johnson R; Bundred N
Eur J Surg Oncol; 2014 Jul; 40(7):813-7. PubMed ID: 24797703
[TBL] [Abstract][Full Text] [Related]
4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
5. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P
Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic mapping and sentinel lymphadenectomy in early stage breast carcinoma.
Altinyollar H; Kapucuoglu N; Pak I; Berberoglu U
J Exp Clin Cancer Res; 2000 Jun; 19(2):141-4. PubMed ID: 10965808
[TBL] [Abstract][Full Text] [Related]
7. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer.
Noguchi M; Ohta N; Koyasaki N; Taniya T; Miyazaki I; Mizukami Y
Cancer; 1991 Nov; 68(9):1918-25. PubMed ID: 1655229
[TBL] [Abstract][Full Text] [Related]
9. [Lobular invasive breast cancer prognostic factors: About 940 patients].
Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É
Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
11. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
12. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ
Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492
[TBL] [Abstract][Full Text] [Related]
13. Treatment and survival of female patients with nonpalpable breast carcinoma.
Tinnemans JG; Wobbes T; Holland R; Hendriks JH; Van der Sluis RF; De Boer HH
Ann Surg; 1989 Feb; 209(2):249-53. PubMed ID: 2537064
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings in nonpalpable invasive breast cancer.
McKinney CD; Frierson HF; Fechner RE; Wilhelm MC; Edge SB
Am J Surg Pathol; 1992 Jan; 16(1):33-6. PubMed ID: 1309412
[TBL] [Abstract][Full Text] [Related]
15. Axillary lymph node dissection in pT1 breast cancer: a retrospective analysis of 315 patients and review of the literature.
Witt A; Obwegeser R; Auerbach L; Tempfer C; Yavuz D; Kubista E
Wien Klin Wochenschr; 2002 Jun; 114(10-11):387-90. PubMed ID: 12708092
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years.
Intra M; Rotmensz N; Veronesi P; Colleoni M; Iodice S; Paganelli G; Viale G; Veronesi U
Ann Surg; 2008 Feb; 247(2):315-9. PubMed ID: 18216539
[TBL] [Abstract][Full Text] [Related]
18. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
[TBL] [Abstract][Full Text] [Related]
19. [Microinvasive ductal carcinoma of the breast. Role of axillary lymph node dissection].
Le Bouëdec G; Penault-Llorca F; de Latour M; Joubert J; Kauffmann P; Pomel C; Dauplat J
J Gynecol Obstet Biol Reprod (Paris); 1999 Feb; 28(1):10-6. PubMed ID: 10394511
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting non-sentinel lymph node involvement in sentinel node positive breast carcinoma.
Durak MG; Akansu B; Akin MM; Sevınç AI; Koçdor MA; Saydam S; Harmancioğlu O; Ellıdokuz H; Bekış R; Canda T
Turk Patoloji Derg; 2011; 27(3):189-95. PubMed ID: 21935867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
